PSMA tracers for cancer radiotherapy
Prostate-specific membrane antigen (PSMA) is a promising biomarker expressed on many human prostate cancers. We synthesize novel agents for PSMA targeting, conjugate radioligands to PSMA-binding molecules, and develop strategies to improve the pharmacokinetics of PSMA tracers. These agents are potentially useful for diagnosis of PSMA-positive prostate cancer, and for targeted alpha-emitter radiotherapy with actinium-225.
Project publications:
Osborne, et al. Repeatability of [68Ga]DKFZ11-PSMA PET scans for detecting prostate-specific membrane antigen-positive prostate cancer. Mol Imaging Biol. 2017 Dec;19(6):944-951.
Kalidindi, et al. A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2642-2651.
Korsen, et al. Molecular imaging of neuroendocrine prostate cancer by targeting delta-like ligand 3. J Nucl Med. 2022 Jan 20.